報價延遲最少15分鐘:2025/08/15 06:38 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.4
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-333.31/--
|
|
企業價值
92.95M
|
| 資產負債 |
|
每股賬面淨值
1.56
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/15 06:38 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes. |
